{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:58:08Z","timestamp":1783763888797,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Exc 257"],"award-info":[{"award-number":["Exc 257"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB TR128"],"award-info":[{"award-number":["SFB TR128"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","award":["NN"],"award-info":[{"award-number":["NN"]}],"id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["NN"],"award-info":[{"award-number":["NN"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008426","name":"Friedrich-Baur-Stiftung","doi-asserted-by":"publisher","award":["NN"],"award-info":[{"award-number":["NN"]}],"id":[{"id":"10.13039\/501100008426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["NN"],"award-info":[{"award-number":["NN"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Verein zur Therapieforschung f\u00fcr MS Kranke","award":["NN"],"award-info":[{"award-number":["NN"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12974-019-1521-5","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T09:03:10Z","timestamp":1564045390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study"],"prefix":"10.1186","volume":"16","author":[{"given":"Frederike C.","family":"Oertel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Outteryck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Knier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Borisow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bellmann-Strobl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Blaschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Jarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Reindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Meinl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Hohlfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9768-014X","authenticated-orcid":false,"given":"Alexander U.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"K\u00fcmpfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Havla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"1521_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1474-4422(15)00334-8","volume":"15","author":"R Hohlfeld","year":"2016","unstructured":"Hohlfeld R, Dornmair K, Meinl E, Wekerle H. The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. Lancet Neurol. 2016;15:198\u2013209.","journal-title":"Lancet Neurol"},{"key":"1521_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fneur.2018.00217","volume":"9","author":"GR Dos Passos","year":"2018","unstructured":"Dos Passos GR, Oliveira LM, da Costa BK, Apostolos-Pereira SL, Callegaro D, Fujihara K, et al. MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol. 2018;9:217.","journal-title":"Front Neurol"},{"key":"1521_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15:134.","journal-title":"J Neuroinflammation"},{"key":"1521_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","volume":"8","author":"P Peschl","year":"2017","unstructured":"Peschl P, Bradl M, H\u00f6ftberger R, Berger T, Reindl M. Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Front Immunol. 2017;8:529.","journal-title":"Front Immunol"},{"key":"1521_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/acn3.164","volume":"2","author":"M Spadaro","year":"2015","unstructured":"Spadaro M, Gerdes LA, Mayer MC, Ertl-Wagner B, Laurent S, Krumbholz M, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol. 2015;2:295\u2013301.","journal-title":"Ann Clin Transl Neurol"},{"key":"1521_CR6","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458515622986","volume":"22","author":"S Jarius","year":"2016","unstructured":"Jarius S, Metz I, K\u00f6nig FB, Ruprecht K, Reindl M, Paul F, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in \u201cpattern II multiple sclerosis\u201d and brain biopsy findings in a MOG-IgG-positive case. Mult Scler. 2016;22:1541\u20139.","journal-title":"Mult Scler"},{"key":"1521_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ana.25291","volume":"84","author":"M Spadaro","year":"2018","unstructured":"Spadaro M, Winklmeier S, Beltr\u00e1n E, Macrini C, H\u00f6ftberger R, Schuh E, et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol. 2018;84:315\u201328.","journal-title":"Ann Neurol"},{"key":"1521_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","volume":"25","author":"R Narayan","year":"2018","unstructured":"Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;25:66\u201372.","journal-title":"Mult Scler Relat Disord"},{"key":"1521_CR9","doi-asserted-by":"crossref","unstructured":"Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol. 2018;9:888.","DOI":"10.3389\/fneur.2018.00888"},{"key":"1521_CR10","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","volume":"90","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90:e1858\u201369.","journal-title":"Neurology."},{"key":"1521_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","volume":"13","author":"F Pache","year":"2016","unstructured":"Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13:282.","journal-title":"J Neuroinflammation"},{"key":"1521_CR12","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","volume":"2","author":"SS Zamvil","year":"2015","unstructured":"Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015;2:e62.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1521_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","volume":"75","author":"SHM Hamid","year":"2018","unstructured":"Hamid SHM, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, et al. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol. 2018;75:65\u201371.","journal-title":"JAMA Neurol"},{"key":"1521_CR14","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","volume":"4","author":"R Ogawa","year":"2017","unstructured":"Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4:e322.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1521_CR15","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1212\/NXI.0000000000000412","volume":"5","author":"L Pandit","year":"2018","unstructured":"Pandit L, Mustafa S, Uppoor R, Nakashima I, Takahashi T, Kaneko K. Reversible paraspinal muscle hyperintensity in anti-MOG antibody-associated transverse myelitis. Neurol Neuroimmunol Neuroinflamm. 2018;5:e412.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1521_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00415-016-8333-7","volume":"264","author":"J Havla","year":"2017","unstructured":"Havla J, K\u00fcmpfel T, Schinner R, Spadaro M, Schuh E, Meinl E, et al. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol. 2017;264:139\u201351.","journal-title":"J Neurol"},{"key":"1521_CR17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1177\/1352458514567216","volume":"21","author":"JL Bennett","year":"2015","unstructured":"Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler. 2015;21:678\u201388.","journal-title":"Mult Scler"},{"key":"1521_CR18","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1212\/NXI.0000000000000135","volume":"2","author":"SL Galetta","year":"2015","unstructured":"Galetta SL, Villoslada P, Levin N, Shindler K, Ishikawa H, Parr E, et al. Acute optic neuritis: unmet clinical needs and model for new therapies. Neurol Neuroimmunol Neuroinflamm. 2015;2:e135.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1521_CR19","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1212\/NXI.0000000000000449","volume":"5","author":"T Oberwahrenbrock","year":"2018","unstructured":"Oberwahrenbrock T, Traber GL, Lukas S, Gabilondo I, Nolan R, Songster C, et al. Multicenter reliability of semiautomatic retinal layer segmentation using OCT. Neurol Neuroimmunol Neuroinflamm. 2018;5:e449.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1521_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13167-017-0123-5","volume":"9","author":"FC Oertel","year":"2018","unstructured":"Oertel FC, Zimmermann H, Paul F, Brandt AU. Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. EPMA J. 2018;9:21\u201333.","journal-title":"EPMA J"},{"key":"1521_CR21","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1212\/NXI.0000000000000334","volume":"4","author":"FC Oertel","year":"2017","unstructured":"Oertel FC, Kuchling J, Zimmermann H, Chien C, Schmidt F, Knier B, et al. Microstructural visual system changes in AQP4-antibody\u2013seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm. 2017;4:e334.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"12","key":"1521_CR22","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/jnnp-2018-318382","volume":"89","author":"Frederike C Oertel","year":"2018","unstructured":"Oertel FC, Havla J, Roca-Fern\u00e1ndez A, Lizak N, Zimmermann H, Motamedi S, et al. Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. J Neurol Neurosurg Psychiatry. 2018;89(12):1259-1265.","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"1521_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8:184.","journal-title":"J Neuroinflammation"},{"key":"1521_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/1352458514538110","volume":"21","author":"S Schippling","year":"2015","unstructured":"Schippling S, Balk LJ, Costello F, Albrecht P, Balcer L, Calabresi PA, et al. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria. Mult Scler. 2015;21:163\u201370.","journal-title":"Mult Scler"},{"key":"1521_CR25","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1212\/WNL.0000000000002774","volume":"86","author":"A Cruz-Herranz","year":"2016","unstructured":"Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016;86:2303\u20139.","journal-title":"Neurology."},{"key":"1521_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u201389.","journal-title":"Neurology."},{"key":"1521_CR27","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00415-016-8127-y","volume":"263","author":"LJ Balk","year":"2016","unstructured":"Balk LJ, Cruz-Herranz A, Albrecht P, Arnow S, Gelfand JM, Tewarie P, et al. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. J Neurol. 2016;263:1323\u201331.","journal-title":"J Neurol"},{"key":"1521_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, Jorge FM de H, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474\u201381.","journal-title":"Neurology."},{"key":"1521_CR29","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1352458514555785","volume":"21","author":"R H\u00f6ftberger","year":"2015","unstructured":"H\u00f6ftberger R, Sepulveda M, Armangue T, Blanco Y, Rost\u00e1sy K, Cobo Calvo A, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015;21:866\u201374.","journal-title":"Mult Scler"},{"key":"1521_CR30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","volume":"87","author":"T Akaishi","year":"2016","unstructured":"Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry. 2016;87:446\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1521_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-007766","volume":"5","author":"H Nakajima","year":"2015","unstructured":"Nakajima H, Motomura M, Tanaka K, Fujikawa A, Nakata R, Maeda Y, et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open. 2015;5:e007766.","journal-title":"BMJ Open"},{"key":"1521_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jneuroim.2016.02.004","volume":"293","author":"T Akaishi","year":"2016","unstructured":"Akaishi T, Nakashima I, Takeshita T, Mugikura S, Sato DK, Takahashi T, et al. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. J Neuroimmunol. 2016;293:28\u201333.","journal-title":"J Neuroimmunol"},{"key":"1521_CR33","doi-asserted-by":"crossref","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 27;13(1):280.","DOI":"10.1186\/s12974-016-0718-0"},{"key":"1521_CR34","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","volume":"125","author":"J Jitprapaikulsan","year":"2018","unstructured":"Jitprapaikulsan J, Chen JJ, Flanagan EP, Tobin WO, Fryer JP, Weinshenker BG, et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis. Ophthalmology. 2018;125:1628\u201337.","journal-title":"Ophthalmology."},{"issue":"4","key":"1521_CR35","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","volume":"1","author":"Sudarshini Ramanathan","year":"2014","unstructured":"Ramanathan S, Reddel SW, Henderson A, Parratt JDE, Barnett M, Gatt PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2014;1(4):e40.","journal-title":"Neurology - Neuroimmunology Neuroinflammation"},{"key":"1521_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1212\/WNL.0000000000000545","volume":"83","author":"AU Brandt","year":"2014","unstructured":"Brandt AU, Oberwahrenbrock T, Kadas EM, Lagr\u00e8ze WA, Paul F. Dynamic formation of macular microcysts independent of vitreous traction changes. Neurology. 2014;83:73\u20137.","journal-title":"Neurology."},{"issue":"8","key":"1521_CR37","doi-asserted-by":"publisher","first-page":"e71145","DOI":"10.1371\/journal.pone.0071145","volume":"8","author":"Falko Kaufhold","year":"2013","unstructured":"Kaufhold F, Zimmermann H, Schneider E, Ruprecht K, Paul F, Oberwahrenbrock T, et al. Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of multiple sclerosis. PLoS One 2013;6;8(8):e71145.","journal-title":"PLoS ONE"},{"key":"1521_CR38","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1352458515593406","volume":"22","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016;22:470\u201382.","journal-title":"Mult Scler"},{"key":"1521_CR39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12974-016-0746-9","volume":"13","author":"CM Felix","year":"2016","unstructured":"Felix CM, Levin MH, Verkman AS. Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G. J Neuroinflammation. 2016;13:275.","journal-title":"J Neuroinflammation"},{"key":"1521_CR40","doi-asserted-by":"crossref","unstructured":"Chien C, Scheel M, Schmitz-H\u00fcbsch T, Borisow N, Ruprecht K, Bellmann-Strobl J, et al. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. Mult Scler. 2018:1352458518815596.","DOI":"10.1177\/1352458518815596"},{"key":"1521_CR41","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","volume":"3","author":"M Spadaro","year":"2016","unstructured":"Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3:e257.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1521_CR42","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1212\/NXI.0000000000000335","volume":"4","author":"P K\u00f6rtv\u00e9lyessy","year":"2017","unstructured":"K\u00f6rtv\u00e9lyessy P, Breu M, Pawlitzki M, Metz I, Heinze H-J, Matzke M, et al. ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports. Neurol Neuroimmunol Neuroinflamm. 2017;4:e335.","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1521-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-019-1521-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1521-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T23:04:12Z","timestamp":1595545452000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-019-1521-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1521"],"URL":"https:\/\/doi.org\/10.1186\/s12974-019-1521-5","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,25]]},"assertion":[{"value":"13 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Twenty-four patients were seen at four university tertiary care centers specialized in neuroimmunological diseases (Institute of clinical Neuroimmunology, Ludwig- Maximilians University (LMU), Munich, NeuroCure Clinical Research Center, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Germany; Department of Neurology, University of Lille Hospital, Lille, France; Department of Neurology, Klinikum Rechts der Isar, Technische Universit\u00e4t M\u00fcnchen (TUM), Munich, Germany). Written informed consent was obtained from all patients participating in the study. The local ethics committees approved the study protocol in accordance with the Declaration of Helsinki (1964) in its currently applicable version.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JH reports a grant for OCT research from the Friedrich-Baur-Stiftung; personal fees and non-financial support from Merck, Novartis, Roche, Bayer Healthcare, Santhera, Biogen, Sanofi Genzyme; and non-financial support of the Guthy-Jackson Charitable Foundation, all outside the submitted work. FCO was an employee of Nocturne UG, unrelated to this work. OO reports grant for research from Novartis-Pharma and grants and personal fees from Biogen, Genzyme, Merck, Novartis-Pharma, and Teva-Pharma, outside the submitted work. BK reports grants from the Bundesministerium f\u00fcr Bildung und Forschung (Kompetenznetz Multiple Sklerose KKNMS), intramural funding from the Technical University of Munich (KKF program) and a grant from Novartis unrelated to this study. HZ reports a research grant from Novartis related to this study and speaking fees from Teva unrelated to this study. LB has nothing to disclose. JBS has received travel grants and speaking fees from Bayer Healthcare, Biogen Idec, Merck Serono, Sanofi-Aventis\/Genzyme, Teva Pharmaceuticals unrelated to this study. SJ has nothing to disclose. The Neurological Research Laboratory (Medical University of Innsbruck and Tirol Kliniken, MR) receives payments for antibody assays (AQP4- and anti-neuronal antibodies) and for AQP4- and MOG-antibody validation experiments organized by Euroimmun (Germany). KR was supported by the German Ministry of Education and Research (BMBF\/KKNMS, Competence Network Multiple Sclerosis) and has received research support from Novartis and Merck Serono as well as speaking fees and travel grants from Guthy Jackson Charitable Foundation, Bayer Healthcare, Biogen Idec, Merck Serono, Sanofi-Aventis\/Genzyme, Teva Pharmaceuticals, Roche and Novartis. EM received an honorarium from Roche, Novartis and Genzyme, and grant support from Novartis and Genzyme. RH received research grants and\/or speaker honoraria from Actelion, Genzyme-Sanofi, Novartis, Immunic, Roche. FP reports research grants and speaker honoraria from Bayer, Teva, Genzyme, Merck, Novartis, MedImmune and is a member of the steering committee of the OCTIMS study (Novartis), all unrelated to this work. AUB is the founder and holds shares of Motognosis and Nocturne. He is named as an inventor on several patent applications describing serum biomarkers for MS, perceptive visual computing for tracking of motor dysfunction and OCT image analysis. TK received travel expenses and personal compensations from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis\/Genzyme, Roche, and Biogen as well as grant support from Bayer-Schering AG, Novartis and Chugai Pharma, unrelated to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}